Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bigioni

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Molecular Pharmacology|September 1, 1996
Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformationF Animati, F Arcamone, M Bigioni, et al.
Bioorganic & Medicinal Chemistry|March 12, 2002
Novel anthracycline oligosaccharides: influence of chemical modifications of the carbohydrate moiety on biological activityA Cipollone, M Berettoni, M Bigioni, et al.
Biochemical Pharmacology|May 30, 2001
A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogueM Bigioni, C Salvatore, A Bullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenograftsG Pratesi, M De Cesare, C Caserini, et al.
Biochemical Pharmacology|March 7, 2001
Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharidesF Arcamone, F Animati, M Bigioni, et al.
Journal of the National Cancer Institute|August 20, 1997
Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivoF Arcamone, F Animati, M Berettoni, et al.
Cell Death & Disease|February 26, 2016
Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancerT Colangelo, G Polcaro, P Ziccardi, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Molecular Pharmacology|September 1, 1996
Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformationF Animati, F Arcamone, M Bigioni, et al.
Bioorganic & Medicinal Chemistry|March 12, 2002
Novel anthracycline oligosaccharides: influence of chemical modifications of the carbohydrate moiety on biological activityA Cipollone, M Berettoni, M Bigioni, et al.
Biochemical Pharmacology|May 30, 2001
A comparative study of cellular and molecular pharmacology of doxorubicin and MEN 10755, a disaccharide analogueM Bigioni, C Salvatore, A Bullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenograftsG Pratesi, M De Cesare, C Caserini, et al.
Biochemical Pharmacology|March 7, 2001
Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharidesF Arcamone, F Animati, M Bigioni, et al.
Journal of the National Cancer Institute|August 20, 1997
Doxorubicin disaccharide analogue: apoptosis-related improvement of efficacy in vivoF Arcamone, F Animati, M Berettoni, et al.
Cell Death & Disease|February 26, 2016
Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancerT Colangelo, G Polcaro, P Ziccardi, et al.
Pageof 3